A total of 20 investigational drugs secured a place on the European Medicines Agency’s PRIME (priority medicines) scheme in 2020, with some of them targeting new therapeutic areas and indications. The margin is small, but that’s the most that have been accepted in any year since the scheme began in 2016.
While the number of applications reviewed for entry onto the scheme was similar to that in the previous two years, the rejection rate –